Quarterly report pursuant to Section 13 or 15(d)

Business Acquisition (Details Narrative)

v3.21.1
Business Acquisition (Details Narrative)
$ in Thousands
Oct. 23, 2020
USD ($)
ft²
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Estimated consideration, total $ 2,500    
Good will 901 $ 901 $ 901
Indefinite-lived intangible asset 1,599    
Consulting Agreement [Member] | Mr. Gurnani [Member]      
Aggregate cost consideration 300    
CLIA License [Member]      
Indefinite-lived intangible asset 1,300    
Plaza Medical Laboratory Corp [Member]      
Cash consideration on acquisition $ 2,500    
Laboratory square foot | ft² 4,000